IBDEI0J7 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9019,2)
 ;;=^119344
 ;;^UTILITY(U,$J,358.3,9020,0)
 ;;=245.1^^38^509^18
 ;;^UTILITY(U,$J,358.3,9020,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9020,1,4,0)
 ;;=4^SUBACUTE THYROIDITIS
 ;;^UTILITY(U,$J,358.3,9020,1,5,0)
 ;;=5^245.1
 ;;^UTILITY(U,$J,358.3,9020,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,9021,0)
 ;;=252.1^^38^509^11
 ;;^UTILITY(U,$J,358.3,9021,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9021,1,4,0)
 ;;=4^HYPOPARATHYROIDISM
 ;;^UTILITY(U,$J,358.3,9021,1,5,0)
 ;;=5^252.1
 ;;^UTILITY(U,$J,358.3,9021,2)
 ;;=^60635
 ;;^UTILITY(U,$J,358.3,9022,0)
 ;;=252.01^^38^509^8
 ;;^UTILITY(U,$J,358.3,9022,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9022,1,4,0)
 ;;=4^HYPERPARATHYROID,PRIMARY
 ;;^UTILITY(U,$J,358.3,9022,1,5,0)
 ;;=5^252.01
 ;;^UTILITY(U,$J,358.3,9022,2)
 ;;=^331439
 ;;^UTILITY(U,$J,358.3,9023,0)
 ;;=252.02^^38^509^13
 ;;^UTILITY(U,$J,358.3,9023,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9023,1,4,0)
 ;;=4^HYPRPRTHYRD NONRENAL,SEC
 ;;^UTILITY(U,$J,358.3,9023,1,5,0)
 ;;=5^252.02
 ;;^UTILITY(U,$J,358.3,9023,2)
 ;;=^331440
 ;;^UTILITY(U,$J,358.3,9024,0)
 ;;=226.^^38^509^2
 ;;^UTILITY(U,$J,358.3,9024,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9024,1,4,0)
 ;;=4^BENIGN NEOPLASM THYROID
 ;;^UTILITY(U,$J,358.3,9024,1,5,0)
 ;;=5^226.
 ;;^UTILITY(U,$J,358.3,9024,2)
 ;;=^267686
 ;;^UTILITY(U,$J,358.3,9025,0)
 ;;=240.0^^38^509^6
 ;;^UTILITY(U,$J,358.3,9025,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9025,1,4,0)
 ;;=4^GOITER,SIMPLE
 ;;^UTILITY(U,$J,358.3,9025,1,5,0)
 ;;=5^240.0
 ;;^UTILITY(U,$J,358.3,9025,2)
 ;;=^259806
 ;;^UTILITY(U,$J,358.3,9026,0)
 ;;=242.31^^38^509^5
 ;;^UTILITY(U,$J,358.3,9026,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9026,1,4,0)
 ;;=4^GOITER W/ CRISIS,TOX NOD
 ;;^UTILITY(U,$J,358.3,9026,1,5,0)
 ;;=5^242.31
 ;;^UTILITY(U,$J,358.3,9026,2)
 ;;=^267804
 ;;^UTILITY(U,$J,358.3,9027,0)
 ;;=242.91^^38^509^24
 ;;^UTILITY(U,$J,358.3,9027,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9027,1,4,0)
 ;;=4^THYROTOX NOS W CRISIS
 ;;^UTILITY(U,$J,358.3,9027,1,5,0)
 ;;=5^242.91
 ;;^UTILITY(U,$J,358.3,9027,2)
 ;;=^267812
 ;;^UTILITY(U,$J,358.3,9028,0)
 ;;=245.3^^38^509^23
 ;;^UTILITY(U,$J,358.3,9028,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9028,1,4,0)
 ;;=4^THYROIDITIS,CHR FIBROUS
 ;;^UTILITY(U,$J,358.3,9028,1,5,0)
 ;;=5^245.3
 ;;^UTILITY(U,$J,358.3,9028,2)
 ;;=^267821
 ;;^UTILITY(U,$J,358.3,9029,0)
 ;;=245.9^^38^509^22
 ;;^UTILITY(U,$J,358.3,9029,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9029,1,4,0)
 ;;=4^THYROIDITIS NOS
 ;;^UTILITY(U,$J,358.3,9029,1,5,0)
 ;;=5^245.9
 ;;^UTILITY(U,$J,358.3,9029,2)
 ;;=^119340
 ;;^UTILITY(U,$J,358.3,9030,0)
 ;;=252.00^^38^509^9
 ;;^UTILITY(U,$J,358.3,9030,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9030,1,4,0)
 ;;=4^HYPERPARATHYROIDISM NOS
 ;;^UTILITY(U,$J,358.3,9030,1,5,0)
 ;;=5^252.00
 ;;^UTILITY(U,$J,358.3,9030,2)
 ;;=^331438
 ;;^UTILITY(U,$J,358.3,9031,0)
 ;;=794.6^^38^510^1
 ;;^UTILITY(U,$J,358.3,9031,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9031,1,4,0)
 ;;=4^ABN ENDOCRINE STUDY NEC
 ;;^UTILITY(U,$J,358.3,9031,1,5,0)
 ;;=5^794.6
 ;;^UTILITY(U,$J,358.3,9031,2)
 ;;=^273448
 ;;^UTILITY(U,$J,358.3,9032,0)
 ;;=783.1^^38^510^2
 ;;^UTILITY(U,$J,358.3,9032,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9032,1,4,0)
 ;;=4^ABNORMAL WEIGHT GAIN
 ;;^UTILITY(U,$J,358.3,9032,1,5,0)
 ;;=5^783.1
 ;;^UTILITY(U,$J,358.3,9032,2)
 ;;=^998
 ;;^UTILITY(U,$J,358.3,9033,0)
 ;;=780.53^^38^510^37
 ;;^UTILITY(U,$J,358.3,9033,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9033,1,4,0)
 ;;=4^SLEEP APNEA W/ HYPERSOMNIA
 ;;^UTILITY(U,$J,358.3,9033,1,5,0)
 ;;=5^780.53
 ;;
 ;;$END ROU IBDEI0J7
